The Study on Local Thermo-therapy with CT Measure Temperature: the Pharmacokinetics Study of Iohexolthermosensitive Liposomes During Local Thermotherapy

Zhang Bin-gjie1*, Li Mu1, Gao Jing2, Zeng Yong2, Yu Fei3 and Zhuang Lu-ning3

1Department of Neurosurgery, Tianjin First Central Hospital, Tianjin - 300 192 China.
2Tianjin Institute Pharmaceuticals Research, Tianjin - 300 193, China.
3School of Chemical Engineering and Technology, Tianjin University, Tianjin - 300 193, China.

(Received: 03 March 2013; accepted: 14 April 2013)

To study on using CT measure temperature during local thermo-therapy, we study the pharmacokinetics of intravenous injecting iohexol thermosensitive in rats. Heating group and non-heating group use C6 Glioma model rats, the heated to 43°C and normal temperature Normal rats are intravenous injected with iohexolstandard product iohexol thermosensitive liposome, the t1/2 of heating group prolongs significantly compared with the non-heating group. The AUC increases significantly. The AUC of heating group increases significantly compared with the standard product group, demonstrating that under the same dose condition, compared with iv. standard product, iohexol thermosensitive liposome can prolongs the time of iohexol in blood circulation. The thermosensitive liposome encapsulated with iohexol in C6 Glioma model are release theirs content sharply in heat group when the local tumor is heated.

Key words: Iohexol; Thermosensitive liposome; Pharmacokinetics, CT, Measure temperature.

Intravenous injects freeze-dried needles including iohexol after heating the tumor local to above 43°C (the convert temperature of thermosensitive liposome), observe the release and its effects to the pharmacokinetics of iohexol encapsuled in thermosensitive liposome above covert temperature (heat) and body temperature, provides the theoretical basis for the CT measure and control temperature during local thermotherapy.

MATERIALS AND METHODS

Drugs

Thermosensitive liposome freeze-dried needles compounded with CT contrast agents (iohexol), thermosensitive liposome. Specifications: 2ml per bottle, including 372 mg/ml, Batch number: 1st batch, provided by tianjin institute pharmaceuticals research. Iohexol(Zhejiang starry people Co., LTD, Batch number 070819), Hydroxyl styrene-acrylic ester (PP, Sigma company products, purity >99%), Tofu helicid (Batch number 050301, content 97.0%, Kunming YunKe pharmaceutical Co., LTD) (ethylene glycol) – 400, Ethyl acetate is analysis alcohol, reagent for HPLC is chromatographic pure.

Animals

C6 glioma model (SD strains), provided by Tianjin First Central Hospital HealDepartment Acute and Serious illness Key Laboratories. Normal SD strains rats, bought in the Chinese Academy of Medical Science. All animals usage of male and female, body weight 200–250g (Experimental animals qualified number: 0001662).

Instrument

Thermostatic circulation water bath (Shanghai medical equipment factory) Peristaltic
pump (Shanghai faith instrument Co., LTD). Homemade u-shaped capillary. HPLC testing instruments (Series b ! pump, SHIMADZU SPD-10A ultraviolet detector, Lab Alliance AS-3000 automatic sampler, ANASTAR chromatographic data stations; LD - 5 type low speed centrifuge (Beijing medical centrifuge plant production); Sartorius BS series electronic balance; TGL - 16C centrifuge table high speed).

**EXPERIMENTAL**

**Design**

C6 glioma model rats are divided into 2 groups randomly, the first group is treated with opening craniotomy window, expose tumors, connect the homemade u-shaped capillary with the thermostatic circulation baths and peristaltic pump, heat the tumor local, let the temperature arrive at above 43!, intravenous inject freeze-dried needles after 20min heat, continue to heat for 10min; the second group is treated with opening craniotomy window but no heating, intravenous inject freeze-dried needles; And set another normal rats intravenous inject standard product solution including iohexol (ethylene glycol) – 400, join iohexol, dilute it to 10ml with injection water. Three groups of rats are all intravenous injected 2ml/200g weight, equivalent to iohexol 3720 mg/kg. Picks before giving drugs (0h), after giving drugs 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8h respectively from venous blood, heparin anticoagulation, measure blood medicine density after separating plasma regularly.

**HPLC assay blood samples determination**

Blood sample pretreatment Iohexol: Take plasma 10µl, 10 times diluted with blank plasma, join Tofu helicid internal standard solution (10mg/ml) 10µl, blending, join 300µl methanol, vortex oscillation 30 seconds, Room-temperature placed 30min, 12000r/min centrifugal 10min, take supernatant fluid 200µl, join 800µl no ion water, centrifugal again 2min, into sample analysis. Standard curve preparation: Weigh out iohexol standard product 100mg precisely, made into 10mg/ml reserve liquid by water. Dilute reserve liquid and prepare plasma sample including iohexol with mass concentration is 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000, 2000µg/ml. Following "2.2.1" start blood sample processing and analysis, use the ratio of iohexol and internal standard chromatographic peak area to calculate and work out the linear regression equation and its correlated coefficient.

**Methods recovery**

Prepare the plasma sample including iohexol which mass concentration is 10050 and 500µg/ml, determine after pretreatment, put it into standard curve regression equation, calculate the titer, recovery (%) = (determined concentration/join concentration) × 100%.

**Rats blood drug concentration measurement and Drug metabolic parameters calculation**

The three group’s rats blood sample are processed following the "2.2.1" and then into sample analysis, put the measured peak area ratio into the regression equation to caculate the concentration. Fitting by the 3p87 pharmacokinetic programs made by China Drugs Institute, and caculate the correlian drug metabolism kinetic parameters, among them the Cmax, Tmax are calculated by actual measured value, AUC is caculated by the trapezoidal area of law.

**RESULTS**

**Specificity of chromatographic method**

Under the above chromatographic conditions, iohexol, internal standard and plasma impurity peak get good separation, Iohexol’s retention time (tR) is 9.8min, internal standard’s retention time (tR) is 15.3min (figure 1). Use the ratio of chromatographic peak A as the abscissa denotes, mass concentration of iohexol (ug/ml) as the y-coordinate, Iohexol’s standard curve: Y=0.0026X+0.0095, r=0.9992. Demonstrates that iohexol in 1^2000ug/ml range linear good, the method recovery of iohexol 10, 50 and 500ug/ml is (78.73±10.05, 102.10±6.34 and 107.33±7.20)%.

**Drug metabolism kinetic parameters**

The blood drug concentration of iohexol in rats bodies see table 1, the blood drug concentration - time curves of iohexol see Figure 2. Pharmacokinetic computer program 3p87 is used to do data processing, after model fitting, the AIC minimum principle is used to determine the blood drug concentration of iohexol liposome after intravenous injected into rats bodies are both match the one room model, the pharmacokinetic parameters of iohexol see table 2.

**Experimental results of pharmacokinetics**
BIN-GJIE et al.: STUDY OF THERMO-THERAPY


Fig. 1. Iohexol HPLC chromatograms

(1 - iohexol, 2 - internal standard, t_R1=9.8 min, t_R2=15.3 min)
Table 1. Rats plasma iohexol concentration after i.v. liposome freeze-dried needle ($\bar{x} \pm s.d., n=3$)

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>Heating group</th>
<th>Non-heating group</th>
<th>Standard product group</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.08</td>
<td>13.67±0.58</td>
<td>15.33±0.31</td>
<td>12.85±0.10</td>
</tr>
<tr>
<td>0.25</td>
<td>11.80±0.46</td>
<td>11.93±0.17</td>
<td>7.67±0.04</td>
</tr>
<tr>
<td>0.5</td>
<td>10.16±0.39</td>
<td>6.11±0.06</td>
<td>4.32±0.04</td>
</tr>
<tr>
<td>1.5</td>
<td>7.62±0.15</td>
<td>2.25±0.03</td>
<td>1.79±0.04</td>
</tr>
<tr>
<td>2</td>
<td>6.71±0.68</td>
<td>0.26±0.12</td>
<td>0.42±0.03</td>
</tr>
<tr>
<td>4</td>
<td>3.97±0.07</td>
<td>0.08±0.03</td>
<td>0.09±0.00</td>
</tr>
<tr>
<td>6</td>
<td>2.50±0.08</td>
<td>0.04±0.01</td>
<td>0.02±0.00</td>
</tr>
</tbody>
</table>

Table 2. iohexol drug metabolism kinetic parameters after i.v. liposome freeze-dried needles ($\bar{x} \pm s.d., n=3$)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Units</th>
<th>Heating group</th>
<th>Non-heating group</th>
<th>Standard product group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ke</td>
<td>l/h</td>
<td>0.29±0.01</td>
<td>1.89±0.18</td>
<td>1.70±0.04</td>
</tr>
<tr>
<td>$t_{1/2}(Ke)$</td>
<td>h</td>
<td>2.38±0.03</td>
<td>0.37±0.03</td>
<td>0.41±0.01</td>
</tr>
<tr>
<td>AUC</td>
<td>(mg/ml)*h</td>
<td>35.45±1.40</td>
<td>11.09±0.25</td>
<td>8.50±0.12</td>
</tr>
<tr>
<td>V(c)</td>
<td>(mg/kg)/(mg/ml)</td>
<td>296.20±12.03</td>
<td>208.26±7.04</td>
<td>294.37±5.20</td>
</tr>
<tr>
<td>CL(s)</td>
<td>mg/kg/h/(mg/ml)</td>
<td>86.16±3.49</td>
<td>393.13±25.66</td>
<td>499.23±4.29</td>
</tr>
</tbody>
</table>

Fig. 2. Time - blood drug concentration curve after i.v. liposome freeze-dried needles (iohexol 3720mg/kg)
in rats bodies show that, freeze-dried needles including iohexol encapsulate with thermosensitive liposome. The t1/2 of heating group prolongs significantly compared with the non-heating group. AUC increases significantly; the AUC of heating group and non-heating group increases significantly compared with the standard product group, demonstrates that under the same dose condition, compared with intravenous inject standard product, freeze-dried needles including iohexol encapsulate with thermosensitive liposome can prolongs the time of iohexol in blood circulation, increases the bioavailability of iohexol; The thermosensitive liposome encapsulated with iohexol in C6 Glioma model are release theirs content sharply in heat group when the local tumor is heated.

**DISCUSSION**

Over half the century, oncology has made great progress around the world, integrated application of all existing possible ways to treat tumor has enjoyed popular support and has been accepted by clinical doctors, it has become the best and most popular model to treat malignant tumor. The cooperation of surgery, radiotherapy, chemotherapy, thermal therapy and biotherapy has made remarkable therapeutic effect in the treatment of many different kinds of malignant tumors (Chen et al., 2003; Mane et al., 1999; Li et al., 1999).

As an auxiliary method to treat malignant tumor, thermal therapy has its distinguishing feature compared with other treatment: low cost, less side-effect, tumor immunity stimulation, curative effect affirmation (Seegenschmiedt et al., 1995). Using thermosensitive liposome as carrier, thermal therapy works with targeted chemotherapy are given increasing attention (Dresen et al., 2005; Takahashi et al., 2002; Aoki et al., 2004). Thermotherapy using laser, radio frequency, microwave or ultrasound focus, and triggers the thermosensitive liposome release the chemotherapeutics locally. Thermosensitive liposome has the character of temperature phase transition and encapsulation, and indiscriminate package of water soluble drug and fat soluble drug, when heated to phase-transition temperature, its content will release. However, the promotion and application of thermotherapy was restricted to a great extent because of the difficulty of temperature measure during treatment. The current thermometric method is using impaired thermometer or using body model to estimate the internal possible temperature distribution. The thermometric way is impaired punctuation way, it is hard to reflect the full view of temperature distribution and it always leads to complication such as infection, bleeding, etc. The body model estimation method could only give a rough estimation of temperature distribution, which is very different from the real temperature. The ideal temperature measure method should be non-impair, time-real and three-dimensional, only in this way, can the cells around the tumor be heated to death, avoiding the existing of “cold area” which leads to recur; meanwhile, only when the temperature is observe and control precisely can the normal tissue be avoid being damaged too much, and reduce the occur of complication. As a result, looking for an ideal method to measure the temperature is an important and difficult problem that is exigent to be solved. With CT is widespread gradually. CT scan could reveal the tumor image without damage, real-time and three dimensional, compared with MRI, quick imaging and low cost is its advantage. CT scan combine with temperature sensitive contrast agent is a promising ideal thermometric method.

Take advantage of temperature phase transition character and packaging character of thermosensitive liposome, its thermal treatment temperature (43°C) as the phase transition temperature, pack the CT contrast agent and chemotherapeutics together, make it a compound thermal sensitive liposome that packing two drugs at the same time; during the local mesenchyme thermal treatment, iv the drug, when the target area reach above the thermal treatment temperature (43°C), the thermosensitive liposome changes its structure, and release its extent, CT would detect the dose changing of local contrast agent, thus it could reveal the heating area effectively, avoid the failure possibility caused by uneven temperature of thermal treatment, and reduce the thermal damage to normal tissue greatly, remove the complication brought by the traditional temperature measurement. While use CT to measure the temperature range, thermosensitive liposome release the chemotherapeutics in the tumor,
express the combined effect of local thermotherapy and chemotherapy targeted heat, enhanced theirs curatives effect, avoid the side-effect of systemic chemotherapy. There isn’t any study that treating tumor under CT observed and controlled temperature, Fosseheim 2000 studied the temperature control feasibility of thermo-sensitive paramagnetic liposome in the MRI oriented thermal treatment(Fosseheim ET AL, 2000; Fosseheim ET AL, 1997; Fosseheim et al, 1998).

This test aims at freeze-dried needles including iohexol encapsulate with thermosensitive liposome, intravenous injects to C6Glioma model rats under the tumor local heating, non-heating condition, observe the pharmacokinetics in rats bodies, and set another normal group rats get intravenous injection with iohexol standard product solution as the comparation. The test of pharmacokinetics in rats bodies shows, iohexol encapsulate with thermosensitive liposome made into freeze-dried needles, can prolong the time of iohexol in blood circulation significantly, increase the absorb of iohexol. It is more favorable for the release of iohexol in rats bodies when the C6Glioma model rat tumor local is heated. We can guess that the structure of thermosensitive liposome have changed in heat point the drug concentration may increase sharply, theirs metabolism form are seem to free iohexol. However, if the drug concentration in the heated local is increased or not, and if the toxicity it brings to each organizations while its bioavailability increased or not, further research in the future is needed.

ACKNOWLEDGEMENTS

This work was financed by the national natural science funds(30772071), thank LIU Chang-xiao academician in Tianjin drug research institute for his guidance and help.

REFERENCES

8. Mane J M., Baucelo J R., Rubio I., Treatment of glioblastoma multiform (GBM) with teniposide (VM26) and Imustine (CCNU) followed by radiotherapy [J] Eur J Cance, 1999; 35: 120.